Drug repurposing, also known as drug repositioning, is a currently tested approach by which new uses are being assigned for already tested drugs. In this case there are antibiotics that are used to combat bacterial infections. However, antibiotics are among the drugs that have been studied for possible antiviral activities. Therefore, the aim of this work is to carry out a review of the studies of antibiotics that could be repositioned for the treatment of viral infections. Among the main antibiotics that have demonstrated antiviral activity are macrolides and glycopeptides. In addition, several antibiotics from the group of tetracyclines, fluoroquinolones, cephalosporins and aminoglycosides have also been studied for their antiviral activity. These antibiotics have demonstrated antiviral activity against both RNA and DNA viruses, including the recent pandemic virus SARS-CoV-2. Some of these antibiotics were selected in addition to its antiviral activity for their immunomodulatory and anti-inflammatory properties. Of the antibiotics that present antiviral activity, in many cases the mechanisms of action are not exactly known. The use of these antibiotics to combat viral infections remains controversial and is not generally accepted, since clinical trials are required to prove its effectiveness. Therefore, there is currently no antibiotic approved as antiviral therapy. Hence is necessary to present the studies carried out on antibiotics that can be repositioned in the future as antiviral drugs.
4 December 2024 in Journal of Medical Microbiology
Introduction.Staphylococcus aureus is a bacterium that colonizes various human sites. The pharynx has been considered as a site of little clinical relevance and little studied. Recently, it has been reported that S. aureus can colonize more the pharynx than the nose. In addition, S. aureus can persist in these sites for prolonged periods of time. Hypothesis. The composition of the pharyngeal and nasal microbiome will differ between persistent, intermittent carriers and non-carriers of S. aureus. Aim. Determine whether the pharyngeal and nasal microbiome is different between carriers and non-carriers of S. aureus. Methodology.S. aureus carriers were monitored by means of pharyngeal and nasal exudates of apparently healthy adult university students for 3 months. Samples from individuals of the same carrier type were pooled, and DNA was extracted and the 16S rRNA was sequenced. The sequences were analysed in MOTHUR v.1.48.0 software, by analysing the percentages of relative abundance in the STAMP 2.1.3 program, in addition to the predictive analysis of metabolic pathways in PICRUSt2. Results. A greater colonization of S. aureus was found in the pharynx than in the nose. The microbiomes of S. aureus carriers and non-carriers do not show significant differences. The main microbiome difference found was between pharyngeal and nasal microbiomes. No significant differences were found in the abundance of the genus Staphylococcus in pharyngeal and nasal S. aureus carriers and non-carriers. The nasal microbiome was found to have more variation compared to the pharyngeal microbiome, which appears to be more stable between individuals and pools. Predictive analysis of metabolic pathways showed a greater presence of Staphylococcus-associated pathways in the nose than in the pharynx. Conclusion.S. aureus can colonize and persist in the pharynx in equal or greater proportion than in the nose. No statistically significant differences were found in the microbiome of the pharyngeal and nasal carriers and non-carriers of S. aureus, but the pharyngeal and nasal microbiomes are different independent of the type of S. aureus carrier or non-carrier. Therefore, the microbiome apparently does not influence the persistence of S. aureus.
Staphylococcus aureus is one of the main bacteria that infect humans. The pediatric population is susceptible to this microorganism; in Mexico there are not enough epidemiological studies on this subject, so the objective of this work was to detect and typify S. aureus strains in an apparently healthy pediatric population of daycare centers and schools. Nasal and pharyngeal exudates were collected to determine the presence of these bacteria and typed as HA-MRSA or CA-MRSA strains by determining SCCmec, mecA gene, Panton-Valentine leucocidin (PVL), phenol-soluble modulin (psm), and spa-type. It was found that 62.55% of the population were carriers of S. aureus, with a higher percentage in the pharynx and in children older than 4 years of age. A total of 7.04% were carriers of MRSA strains, of which 14.64% were HA-MRSA strains and 85.36% were CA-MRSA strains. The strains showed resistance to several antibiotics. About 20% of the MRSA strains had PVL and psm genes. The strains presented a great variety of spa-types. A high number of S. aureus carriers were found in the pediatric population studied, with the presence of CA-MRSA strains, so surveillance and decolonization programs should be established.
Staphylococcus aureus is one of the most important pathogenic bacteria in humans. The nose and pharynx constitute two fundamental ecological niches for this bacterium, supporting the asymptomatic carrier state and acting as sources of infection in susceptible organisms. Colonization dynamics depend on the balance between the bacteria's virulence factors, the host's immune response, and the environment. Colonization is favored by attenuated immune responses, with evidence of partial tolerance and low protective antibody titers. Colonization also appears to depend on the microbiome of the colonized site. Genetic, metabolic, lifestyle, and age factors of the host may also contribute to colonization. Global prevalence rates vary widely depending on the geographic, social, and economic context. Recently, emerging strategies such as the use of phages, microbiome modulation, nanoparticles, gene editing technologies, and vaccines have been developed as promising alternatives to prevent colonization and infection by this bacterium. This review summarizes the current evidence on the factors that allow nasal and pharyngeal colonization of S. aureus, as well as therapeutic perspectives to prevent colonization by this bacterium.
Staphylococcus aureus colonizes the nasal and pharyngeal mucosa of a considerable proportion of the human population, representing a relevant reservoir for the dissemination of antibiotic resistance. This study aimed to determine the prevalence, antibiotic resistance profiles, and molecular characterization of S. aureus strains isolated from the nose and pharynx of healthy individuals of Mexico City, Mexico. Nasal and pharyngeal swabs were taken from 1777 individuals aged between 1 and 99 years. Microbiological identification, antibiotic susceptibility testing, virulence gene detection, SCCmec typing, and spa-typing allowed the characterization of 1459 strains. S. aureus colonization was found in 59.7% of the population, with more of these strains being found in the pharynx than in the nose. MRSA constituted 9.25% of the strains, with a predominance of strains with SCCmec types IV and IVa. The most frequent resistance of S. aureus strains was to penicillin (87.6%), clindamycin (43.4%) and erythromycin (27.2%), with no statistical differences regarding the anatomical sites of isolation. The most frequently found virulence genes were lukE-D, icaA, sdrC, coa, and gyrA. Sixty-two spa-types were identified, and t-189 was the most common. These findings reflect a high colonization rate and genetic diversity, highlighting the importance of considering both anatomical sites in S. aureus surveillance studies.